Physician profile
David W Tessier
NPI 1326483447
$1,672.55
in general payments reported to CMS, 2019-2025
11 companies · $42.18 in 2025
The $42.18 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2022: $78.69 · 2023: $751 · 2024: $611 · 2025: $42.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $487.64 | 2023-2024 | Apretude, Dovato, Rukobia |
| Gilead Sciences, INC. | $476.10 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $271.65 | 2022-2025 | Delstrigo, Pifeltro, Dificid |
| Alkermes, INC. | $213.00 | 2019-2023 | Vivitrol |
| Janssen Biotech, INC. | $56.41 | 2022-2023 | Symtuza |
| Pfizer INC. | $49.17 | 2023-2024 | |
| Abbvie INC. | $44.38 | 2023 | Vraylar |
| Coopersurgical, INC. | $36.88 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Exact Sciences Corporation | $14.38 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $13.89 | 2024 | Zepbound, Jardiance |
| Organon LLC | $9.05 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tessier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.